Table 1.
Effect of bpV(pic) and/or LY294002 treatment on clinical disease and inflammatory parameters in infected animals.
| Treatment | vehicle | bpV(pic) | bpV(pic) + LY294002 | LY294002 |
|---|---|---|---|---|
| CSF bacterial titer (log10 cfu/ml) | 7.9 ± 0.8 (13) | **6.9 ± 0.7 (16) | **6.9 ± 0.9 (12) | 8.0 ± 0.7 (10) |
| Δweight (g) (mock-inf – inf) | 2.4 ± 0.7 (17) | 2.0 ± 1.1 (16) | 2.5 ± 0.9 (15) | 2.4 ± 1.4 (11) |
| Clinical score (1–5) | 3.9 ± 0.2 (17) | 3.9 ± 0.3 (16) | 3.9 ± 0.4 (15) | 4.0 ± 0.0 (11) |
| CSF MPO activity (%infected) | 100 ± 23.4 (7) | 110 ± 27.0 (6) | 78.6 ± 13.6 (10) | 113 ± 22.1 (9) |
| CSF leukocytes (per μl) | 600 ± 245 (6) | 625 ± 386 (4) | 500 ± 743 (4) | 480 ± 164 (5) |
| %Neutrophils | 84.5 ± 9.2 (7) | 92.6 ± 4.8 (7) | 92.9 ± 6.5 (7) | 90.0 ± 3.9 (6) |
| %Monocytes | 10.9 ± 4.7 (7) | 5.7 ± 4.8 (7) | 4.4 ± 5.5 (7) | 7.2 ± 3.3 (6) |
| %Lymphocytes | 4.5 ± 5.0 (7) | 1.7 ± 1.0 (7) | 2.7 ± 2.6 (7) | 2.6 ± 1.4 (6) |
| %Eosinophils | 0.1 ± 0.2 (7) | 0.0 ± 0.0 (7) | 0.0 ± 0.0 (7) | 0.2 ± 0.3 (6) |
| CSF TNF-α (%infected) | 100 ± 11.9 (10) | *41.3 ± 6.2 (11) | **32.8 ± 9.6 (8) | 126 ± 24.5 (8) |
| CSF IL-6 (%infected) | 100 ± 13.6 (10) | ***29.6 ± 6.3 (11) | *49.4 ± 9.4 (8) | 96.4 ± 17.8 (8) |
| CSF IL-10 (%infected) | 100 ± 19.9 (10) | ***22.1 ± 5.6 (11) | **32.8 ± 9.6 (8) | 72.7 ± 11.4 (8) |
All parameters were determined at 18 h p.i. Results are given as mean ± SD for absolute data and mean ± SEM for data expressed relative to infected, vehicle-treated animals (%infected) with number of animals in brackets.
**
P<0.01 and
***
P<0.001 vs. infected, vehicle-treated animals.
LY294002 co-treatment did not reverse the reduction in CSF bacterial titer and cytokine concentrations mediated by bpV(pic) treatment (P>0.05, 1-way ANOVA post-hoc test).